| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 2.34 Billion | USD 4.36 Billion | 6.40% | 2024 |
FrequentlyAsked Questions
HbA1c testing devices are medical instruments that measure glycated hemoglobin levels in blood, providing healthcare professionals with critical information about average blood glucose control over the past two to three months.
The HbA1c testing devices market is expected to be driven by the rising global prevalence of diabetes, increasing adoption of point-of-care testing, technological advancements in diagnostic accuracy, growing awareness of preventive healthcare, and the expansion of home healthcare services.
According to our study, the global HbA1c testing devices market was worth around USD 2.34 billion in 2024 and is predicted to grow to around USD 4.36 billion by 2034.
The CAGR value of the HbA1c testing devices market is expected to be around 6.40% during 2025-2034.
The global HbA1c testing devices market will register the highest revenue contribution from North America during the forecast period.
Key players in the HbA1c testing devices market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Bio-Rad Laboratories Inc., Tosoh Corporation, Arkray Inc., PTS Diagnostics, Bayer AG, Beckman Coulter Inc., Trinity Biotech, Erba Diagnostics Mannheim GmbH, EKF Diagnostics Holdings plc, Diasys Diagnostic Systems GmbH, Transasia Bio-Medicals Ltd., Mindray Medical International Limited, Danaher Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Ortho Clinical Diagnostics, and Quidel Corporation.
The report provides a comprehensive analysis of the HbA1c testing devices market, including an in-depth examination of market drivers, restraints, emerging trends, regional dynamics, and future growth prospects. It also examines the competitive dynamics, technological innovations, regulatory landscape, and healthcare adoption patterns that shape the diabetes diagnostic device market ecosystem.
HappyClients